Skip to main
POAI
POAI logo

POAI Stock Forecast & Price Target

POAI Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Predictive Oncology Inc. is on a growth trajectory, with projected risk-adjusted total revenues set to escalate from $1.5 million in 2024 to $48 million by 2033, reflecting a substantial compound annual growth rate (CAGR) of approximately 20%. The firm anticipates its first risk-adjusted collaboration revenues, primarily from its PEDAL-related preclinical programs, to reach around $9 million in 2025, with expectations of continued revenue growth across its segments. Additionally, the company's impressive advancements in enhancing protein solubility for clients further strengthen its competitive position within the healthcare sector, positioning it favorably for future growth and partnerships.

Bears say

Predictive Oncology Inc reported a net loss of $3.2 million, equivalent to $0.68 per share, for the second quarter of 2024, indicating ongoing financial distress. The company's ability to generate future revenues is jeopardized by potential failures in meeting the expectations of collaborative partners, as well as challenges in obtaining necessary regulatory approvals. Additionally, the recorded impairment of goodwill suggests underlying issues that could further dilute shareholder value and raises concerns about the sustainability of its operations.

POAI has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Predictive Oncology Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Predictive Oncology Inc (POAI) Forecast

Analysts have given POAI a Strong Buy based on their latest research and market trends.

According to 1 analysts, POAI has a Strong Buy consensus rating as of Jun 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Predictive Oncology Inc (POAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.